CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Ocuphire Pharma, Inc. - OCUP CFD

3.31
3.78%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 3.44
Open* 3.45
1-Year Change* 69.95%
Day's Range* 3.1 - 3.45
52 wk Range 1.90-6.60
Average Volume (10 days) 159.29K
Average Volume (3 months) 2.88M
Market Cap 83.82M
P/E Ratio 5.61
Shares Outstanding 21.01M
Revenue 45.27M
EPS 0.71
Dividend (Yield %) N/A
Beta 0.32
Next Earnings Date Nov 2, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 29, 2023 3.31 -0.15 -4.34% 3.46 3.51 3.05
Sep 28, 2023 3.44 -0.37 -9.71% 3.81 3.81 3.38
Sep 27, 2023 3.73 -0.26 -6.52% 3.99 4.10 3.58
Sep 26, 2023 3.99 0.16 4.18% 3.83 4.38 3.83
Sep 25, 2023 3.88 0.02 0.52% 3.86 3.89 3.80
Sep 22, 2023 3.83 -0.04 -1.03% 3.87 3.94 3.80
Sep 21, 2023 3.86 -0.03 -0.77% 3.89 3.92 3.82
Sep 20, 2023 3.94 -0.01 -0.25% 3.95 3.96 3.91
Sep 19, 2023 3.99 0.05 1.27% 3.94 4.01 3.90
Sep 18, 2023 3.94 -0.04 -1.01% 3.98 4.02 3.91
Sep 15, 2023 3.97 0.06 1.53% 3.91 4.05 3.91
Sep 14, 2023 3.99 0.06 1.53% 3.93 4.02 3.79
Sep 13, 2023 3.87 -0.16 -3.97% 4.03 4.07 3.85
Sep 12, 2023 4.05 0.07 1.76% 3.98 4.07 3.97
Sep 11, 2023 4.00 0.01 0.25% 3.99 4.01 3.89
Sep 8, 2023 3.97 0.03 0.76% 3.94 4.07 3.93
Sep 7, 2023 3.95 0.19 5.05% 3.76 3.97 3.76
Sep 6, 2023 3.79 0.00 0.00% 3.79 3.84 3.74
Sep 5, 2023 3.82 -0.11 -2.80% 3.93 3.96 3.78
Sep 1, 2023 3.89 0.01 0.26% 3.88 3.96 3.86

Ocuphire Pharma, Inc. Events

Time (UTC) Country Event
Thursday, November 2, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Ocuphire Pharma Inc Earnings Release
Q3 2023 Ocuphire Pharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 39.85 0.589 0 0 0
Revenue 39.85 0.589 0 0
Total Operating Expense 21.624 23.29 16.292 11.215 20.5377
Selling/General/Admin. Expenses, Total 7.269 8.121 2.818 5.72863 7.42862
Research & Development 14.355 15.173 6.648 5.47678 13.1091
Unusual Expense (Income) -0.004 6.826 0.00959
Operating Income 18.226 -22.701 -16.292 -11.215 -20.5377
Interest Income (Expense), Net Non-Operating -0.009 -33.831 -8.333 2.57957 5.80039
Net Income Before Taxes 18.203 -56.693 -24.62 -8.63543 -14.3685
Net Income After Taxes 17.888 -56.693 -24.62 -8.63543 -14.3685
Net Income Before Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
Net Income 17.888 -56.693 -24.62 -8.63543 -14.3685
Income Available to Common Excl. Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
Income Available to Common Incl. Extra. Items 17.888 -56.693 -24.62 -8.63543 -14.3685
Diluted Net Income 17.888 -56.693 -24.62 -8.63543 -14.3685
Diluted Weighted Average Shares 20.5972 14.8527 4.66111 0.99004 0.68574
Diluted EPS Excluding Extraordinary Items 0.86847 -3.817 -5.282 -8.7223 -20.9534
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 0.86847 -3.81727 -3.81755 -8.71261 -20.9534
Other, Net -0.014 -0.161 0.005 0 0.36875
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3.674 1.749 39.85 0 0
Total Operating Expense 9.063 7.88 5.64 4.538 4.938
Selling/General/Admin. Expenses, Total 4.34 2.285 2.054 1.703 1.776
Research & Development 4.723 5.595 3.586 2.835 3.162
Unusual Expense (Income)
Operating Income -5.389 -6.131 34.21 -4.538 -4.938
Interest Income (Expense), Net Non-Operating 0 0 0 0 -0.004
Other, Net 0.428 0.34 0.046 0.007 0.015
Net Income Before Taxes -4.961 -5.791 34.256 -4.531 -4.927
Net Income After Taxes -4.961 -5.791 33.941 -4.531 -4.927
Net Income Before Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
Net Income -4.961 -5.791 33.941 -4.531 -4.927
Income Available to Common Excl. Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
Income Available to Common Incl. Extra. Items -4.961 -5.791 33.941 -4.531 -4.927
Diluted Net Income -4.961 -5.791 33.941 -4.531 -4.927
Diluted Weighted Average Shares 20.9598 20.9396 23.4819 20.4982 19.5026
Diluted EPS Excluding Extraordinary Items -0.23669 -0.27656 1.44541 -0.22104 -0.25263
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.23669 -0.27656 1.44541 -0.22104 -0.25263
Revenue 3.674 1.749 39.85 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 48.986 26.067 17.668 12.664 15.8997
Cash and Short Term Investments 42.683 24.753 16.399 12.2168 14.7258
Cash & Equivalents 42.634 24.534 16.399 9.21955 8.7443
Short Term Investments 0.049 0.219 2.99722 5.98152
Prepaid Expenses 1.373 1.314 1.269 0.44721 0.55543
Other Current Assets, Total 0.08 0 0.61842
Total Assets 48.992 26.077 17.682 12.9688 16.0429
Property/Plant/Equipment, Total - Net 0.006 0.01 0.014 0.27912 0.11247
Property/Plant/Equipment, Total - Gross 0.025 0.025 0.025 0.55084 0.82159
Accumulated Depreciation, Total -0.019 -0.015 -0.011 -0.27172 -0.70912
Long Term Investments 0.02568 0.03079
Total Current Liabilities 2.753 3.855 3.185 2.9055 3.15255
Accounts Payable 1.069 1.584 1.214 0.48829 0.54752
Accrued Expenses 1.369 1.733 1.971 0.91721 2.60503
Notes Payable/Short Term Debt 0 0.538 0 0 0
Total Liabilities 2.753 3.855 31.149 3.01082 5.48004
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0 27.964 0.10532 2.32749
Total Equity 46.239 22.222 -13.467 9.95795 10.5629
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.002 0.002 0.001 0.0004 0.00375
Additional Paid-In Capital 117.717 111.588 19.207 173.278 165.264
Retained Earnings (Accumulated Deficit) -71.48 -89.368 -32.675 -163.323 -154.687
Other Equity, Total 0.00208 -0.01784
Total Liabilities & Shareholders’ Equity 48.992 26.077 17.682 12.9688 16.0429
Total Common Shares Outstanding 20.8613 18.8458 10.8825 1.00479 0.78179
Other Current Liabilities, Total 0.315 0 1.5
Total Receivables, Net 4.85
Accounts Receivable - Trade, Net 4.85
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 45.399 48.986 14.561 17.891 20.476
Cash and Short Term Investments 39.01 42.683 13.956 17.151 19.381
Cash & Equivalents 38.988 42.634 13.855 17.025 19.246
Prepaid Expenses 1.01 1.373 0.544 0.709 1.095
Other Current Assets, Total 0.078 0.08 0.061 0.031
Total Assets 45.404 48.992 14.568 17.899 20.485
Property/Plant/Equipment, Total - Net 0.005 0.006 0.007 0.008 0.009
Property/Plant/Equipment, Total - Gross 0.025 0.025 0.025 0.025 0.025
Accumulated Depreciation, Total -0.02 -0.019 -0.018 -0.017 -0.016
Total Current Liabilities 4.154 2.753 2.691 3.304 3.213
Accounts Payable 2.221 1.069 1.468 1.886 1.579
Accrued Expenses 1.618 1.369 1.223 1.418 1.419
Notes Payable/Short Term Debt 0 0 0 0 0.215
Total Liabilities 4.154 2.753 2.691 3.304 3.213
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0 0 0 0 0
Total Equity 41.25 46.239 11.877 14.595 17.272
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.002 0.002 0.002 0.002 0.002
Additional Paid-In Capital 118.519 117.717 117.296 115.483 113.233
Retained Earnings (Accumulated Deficit) -77.271 -71.48 -105.421 -100.89 -95.963
Total Liabilities & Shareholders’ Equity 45.404 48.992 14.568 17.899 20.485
Total Common Shares Outstanding 20.9478 20.8613 20.8015 20.0996 19.2136
Total Receivables, Net 5.301 4.85
Accounts Receivable - Trade, Net 5.301 4.85
Short Term Investments 0.022 0.049 0.101 0.126 0.135
Other Current Liabilities, Total 0.315 0.315
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 17.888 -56.693 -24.62 -8.63543 -14.3685
Cash From Operating Activities 14.314 -19.37 -6.797 -10.2771 -18.8386
Cash From Operating Activities 0.004 0.004 0.008 0.04099 0.04821
Non-Cash Items 1.977 37.138 16.669 -1.90774 -4.66764
Changes in Working Capital -5.555 0.181 1.146 0.22505 0.14932
Cash From Investing Activities 0 -0.1 0.539 3.09855 11.911
Capital Expenditures 0 -0.01938 -0.03922
Other Investing Cash Flow Items, Total 0 -0.1 0.539 3.11793 11.9502
Cash From Financing Activities 3.786 27.605 21.12 7.65383 6.77279
Issuance (Retirement) of Stock, Net 4.455 28.578 -0.448 7.65383 6.87279
Net Change in Cash 18.1 8.135 14.862 0.47525 -0.15485
Financing Cash Flow Items -0.131 -1.619 19.371 0 -0.1
Cash Taxes Paid 0 0 0
Cash Interest Paid 0.009 0.002 0
Issuance (Retirement) of Debt, Net -0.538 0.646 2.197
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -5.791 17.888 -16.053 -11.522 -6.595
Cash From Operating Activities -3.646 14.314 -14.477 -9.979 -6.17
Cash From Operating Activities 0.001 0.004 0.003 0.002 0.001
Non-Cash Items 0.831 1.977 1.501 0.983 0.529
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0.009 0.009 0.009 0.005
Changes in Working Capital 1.313 -5.555 0.072 0.558 -0.105
Cash From Investing Activities 0 0 0 0 0
Other Investing Cash Flow Items, Total 0 0 0 0 0
Cash From Financing Activities 0 3.786 3.798 2.47 0.882
Issuance (Retirement) of Stock, Net 0 4.455 4.455 3.093 1.235
Issuance (Retirement) of Debt, Net 0 -0.538 -0.538 -0.538 -0.323
Net Change in Cash -3.646 18.1 -10.679 -7.509 -5.288
Financing Cash Flow Items 0 -0.131 -0.119 -0.085 -0.03

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocuphire Pharma, Inc. Company profile

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Industry: Pharmaceuticals (NEC)

37000 Grand River Ave.
Suite 120
FARMINGTON HILLS
MICHIGAN 48335
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

90.22 Price
+0.400% 1D Chg, %
Long position overnight fee 0.0660%
Short position overnight fee -0.0879%
Overnight fee time 21:00 (UTC)
Spread 0.030

BTC/USD

28,492.05 Price
+4.730% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Gold

1,842.70 Price
-0.380% 1D Chg, %
Long position overnight fee -0.0196%
Short position overnight fee 0.0114%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.53 Price
+1.120% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading